Tag Archives: SITC

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of NSCLC

Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. […]

Read More